Stride Pharmaceutical (603858.SH) releases preliminary results, with net profit attributable to shareholders in the first half of the year expected to be between 4.88 billion yuan and 7.08 billion yuan, representing a year-on-year increase of 110.88% to 205.94%.

China Securities Journal APP reported that Buchang Pharmaceuticals (603858.SH) announced that, according to preliminary calculations by the finance department, it is expected to achieve a net profit attributable to the owners of the parent company of approximately 488 million to 708 million yuan in the first half of 2025. Compared with the same period last year, this will increase by 256.58 million to 476.58 million yuan, a year-on-year increase of 110.88% to 205.94%.